Most Popular
1. It’s a New Macro, the Gold Market Knows It, But Dead Men Walking Do Not (yet)- Gary_Tanashian
2.Stock Market Presidential Election Cycle Seasonal Trend Analysis - Nadeem_Walayat
3. Bitcoin S&P Pattern - Nadeem_Walayat
4.Nvidia Blow Off Top - Flying High like the Phoenix too Close to the Sun - Nadeem_Walayat
4.U.S. financial market’s “Weimar phase” impact to your fiat and digital assets - Raymond_Matison
5. How to Profit from the Global Warming ClImate Change Mega Death Trend - Part1 - Nadeem_Walayat
7.Bitcoin Gravy Train Trend Forecast 2024 - - Nadeem_Walayat
8.The Bond Trade and Interest Rates - Nadeem_Walayat
9.It’s Easy to Scream Stocks Bubble! - Stephen_McBride
10.Fed’s Next Intertest Rate Move might not align with popular consensus - Richard_Mills
Last 7 days
President Donald PUMP Forecast to Win US Presidential Election 2024 - 1st Nov 24
At These Levels, Buying Silver Is Like Getting It At $5 In 2003 - 28th Oct 24
Nvidia Numero Uno Selling Shovels in the AI Gold Rush - 28th Oct 24
The Future of Online Casinos - 28th Oct 24
Panic in the Air As Stock Market Correction Delivers Deep Opps in AI Tech Stocks - 27th Oct 24
Stocks, Bitcoin, Crypto's Counting Down to President Donald Pump! - 27th Oct 24
UK Budget 2024 - What to do Before 30th Oct - Pensions and ISA's - 27th Oct 24
7 Days of Crypto Opportunities Starts NOW - 27th Oct 24
The Power Law in Venture Capital: How Visionary Investors Like Yuri Milner Have Shaped the Future - 27th Oct 24
This Points To Significantly Higher Silver Prices - 27th Oct 24
US House Prices Trend Forecast 2024 to 2026 - 11th Oct 24
US Housing Market Analysis - Immigration Drives House Prices Higher - 30th Sep 24
Stock Market October Correction - 30th Sep 24
The Folly of Tariffs and Trade Wars - 30th Sep 24
Gold: 5 principles to help you stay ahead of price turns - 30th Sep 24
The Everything Rally will Spark multi year Bull Market - 30th Sep 24
US FIXED MORTGAGES LIMITING SUPPLY - 23rd Sep 24
US Housing Market Free Equity - 23rd Sep 24
US Rate Cut FOMO In Stock Market Correction Window - 22nd Sep 24
US State Demographics - 22nd Sep 24
Gold and Silver Shine as the Fed Cuts Rates: What’s Next? - 22nd Sep 24
Stock Market Sentiment Speaks:Nothing Can Topple This Market - 22nd Sep 24
US Population Growth Rate - 17th Sep 24
Are Stocks Overheating? - 17th Sep 24
Sentiment Speaks: Silver Is At A Major Turning Point - 17th Sep 24
If The Stock Market Turn Quickly, How Bad Can Things Get? - 17th Sep 24
IMMIGRATION DRIVES HOUSE PRICES HIGHER - 12th Sep 24
Global Debt Bubble - 12th Sep 24
Gold’s Outlook CPI Data - 12th Sep 24

Market Oracle FREE Newsletter

How to Protect your Wealth by Investing in AI Tech Stocks

What’s Really Wrong With the Thiel Fellowships

Politics / US Politics Jun 20, 2011 - 04:55 AM GMT

By: Ian_Fletcher

Politics Best Financial Markets Analysis ArticleIn case you missed it, the Thiel Foundation, founded by Peter Thiel of PayPal fame, just announced the first batch of winners for its “20 Under 20” fellowship program to pay students to drop out of college for two years to pursue entrepreneurial ideas.

Any number of people have criticized this venture for encouraging kids to drop out of college. Personally, while I think it would be terrible thing if this sort of thing becomes too hip and causes deluded average kids who think the next Google is locked inside their heads to drop out and ruin their educations, it appears that the group chosen is sufficiently elite that a) they may well actually do something useful and b) will succeed no matter what.



Nonetheless, I still think this program is a bad idea, and unlikely to achieve its intended purpose of enhancing innovation in the U.S. (My apologies to the foundation if its purpose is otherwise.) Why? Because its essential strategy consists in smoothing the path of individual geniuses, and this is simply not where the bottleneck to innovation lies in America today.

It’s easy to be distracted by the glamorous entrepreneurs who appear on the covers of business magazines into thinking that they are the sole essence of innovation. Obviously, what they do is important, and I hope they continue to do it. But unfortunately, individual technological entrepreneurship is only the third stage of an innovation “pipeline” whose stages are, roughly:

1. Advances in basic science.

2. Advances in infratechnologies. (I’ll explain what these are in a minute.)

3. Development and sale of new technologies by entrepreneurs.

In the U.S. today, the principal bottleneck in the pipeline is stage two, not three.

What are infratechnologies? They are the crucial, but unpatentable and thus unprofitable, advances that must take place before saleable new technologies can be developed. Because they are unpatentable (or if patentable, infeasible to commercialize directly for other reasons) private industry has little interest in developing them.

Because they are not pure science, academic science funded by the National Science Foundation isn’t that interested either.

America simply doesn’t have a bottleneck at stage three. Our culture and institutions are friendly to for-profit business generally, and entrepreneurship especially, in just about every meaningful way. (Granted, one can quibble about imperfections, but by any reasonable international comparison, we’re just about as friendly as one can get, pace politically motivated whining.)

Similarly, America is probably not where it should be with regards to basic science, but we still lead the world. So there’s not really a bottleneck there, either.

To understand infratechnologies, let’s take an example reported by Gregory Tassey, the economist at the National Bureau of Standards and Technologies (NIST) who is America’s foremost expert on them. In his book The Technology Imperative, he writes:

Measurement-related infratechnologies are a prominent example. For example, a fundamental measurement method called isotope dilution mass spectrometry (IDMS), developed by NIST scientists and others, led to infratechnologies and associated standards in such diverse applications as measurement of sulfur in fossil fuels for compliance with environmental regulations and test methods for cholesterol and other blood elements.

America’s investment in such things for civilian purposes, despite exceptions like NIST, the National Institutes of Health, and the Advanced Research Projects Agency - Energy, is relatively small, and far below what it should be.

What happens when infratechnologies don’t get enough development? Tassey provides a case study:

In 1982, Dr Ronald Levy and colleagues at Stanford University succeeded in treating a chemotherapy-refractory patient with low-grade follicular lymphoma by using high doses of MABs [monoclonal antibodies]. This initial success created hopes that the “magic bullet” against cancer had been found.

However, subsequent efforts at developing therapeutic MABs for various cancers failed. The problem was that the generic mechanism of action was not adequately understood. Many guesses were made in order to rationalize proceeding with drug candidate development. For example, some researchers thought that the monoclonal antibody somehow activated the patient’s immune system because successful treatment provided protection long after the antibody was eliminated from the patient, but no proof of this conjecture was developed.

Such guesses were forced by the fact that the generic technology of MABs was only vaguely understood. Without the underlying technology platform in place, subsequent drug development efforts failed. The result of multiple failures was that both companies and investors lost interest in MABs as a promising therapy. The risk of further failure for additional drug candidates was prohibitively high and therefore they became unattractive candidates for venture capital…

Approximately 10 additional years of government funding by NIH [National Institutes of Health] were required to eventually advance the generic technology to the point that once again private capital was induced to flow into antibody drug development. The major advances were the introduction of recombinant antibody technologies and the development of human and humanized antibodies.

Multiply this bioscience example across all our emerging technologies, from nanotech to biofuels, and you have the true bottleneck to American innovation today. And this is a problem that nurturing young geniuses—whatever else that may accomplish—has very little to do with.

Infratechnologies are, in the language of economics, quasi-public goods. That is, they fall into a difficult category between pure public goods like, say, national security, which it is impossible for any one individual to appropriate, and the pure private goods that are the province of ordinary profit-seeking businesses. Because they are partly public goods, there is a legitimate argument for—horrors!—big government to be involved in supplying them.

This fact tends to drive Silicon Valley libertarians crazy. But if only they would be honest with themselves about the ultimate bases of their own fortunes, they might understand.

Ian Fletcher is the author of the new book Free Trade Doesn’t Work: What Should Replace It and Why (USBIC, $24.95)  He is an Adjunct Fellow at the San Francisco office of the U.S. Business and Industry Council, a Washington think tank founded in 1933.  He was previously an economist in private practice, mostly serving hedge funds and private equity firms. He may be contacted at ian.fletcher@usbic.net.

© 2011 Copyright  Ian Fletcher - All Rights Reserved

Disclaimer: The above is a matter of opinion provided for general information purposes only and is not intended as investment advice. Information and analysis above are derived from sources and utilising methods believed to be reliable, but we cannot accept responsibility for any losses you may incur as a result of this analysis. Individuals should consult with their personal financial advisors.


© 2005-2022 http://www.MarketOracle.co.uk - The Market Oracle is a FREE Daily Financial Markets Analysis & Forecasting online publication.


Post Comment

Only logged in users are allowed to post comments. Register/ Log in